A B S T R A C T
Background: Polycystic kidney disease (PKD) is characterized by urinary tract infections and extrarenal abnormalities such as an increased risk of cancer. As mutations in polycystin-1 and -2 are associated with decreased proliferation of immortalized lymphoblastoid cells in PKD, we investigated whether lymphopenia could be an unrecognized trait of PKD. Methods: We studied 700 kidney transplant recipients with (n ¼ 126) or without PKD at the time of kidney transplantation between 1 January 2003 and 31 December 2014 at Ghent University Hospital. We also studied 204 patients with chronic kidney disease (CKD) with PKD and 204 matched CKD patients without PKD across comparable CKD strata with assessment between 1 January 1999 and 1 February 2016 at three renal outpatient clinics. We compared lymphocyte counts with multiple linear regression analysis to adjust for potential confounders. We analysed flow cytometric immunophenotyping data and other haematological parameters. Results: Lymphocyte counts were 264/mL [95% confidence interval (CI) 144-384] and 345/mL (95% CI 245-445) (both P < 0.001) lower in the end-stage kidney disease (ESKD) and CKD cohort, respectively, after adjustment for age, sex, ln(Creactive protein) and estimated glomerular filtration rate (in the CKD cohort only). In particular, CD8 þ T and B lymphocytes were significantly lower in transplant recipients with versus without PKD (P < 0.001 for both). Thrombocyte and monocyte counts were lower in patients with versus without PKD in both cohorts (P < 0.001 for all analyses except P ¼ 0.01 for monocytes in the ESKD cohort). Conclusion: PKD is characterized by distinct cytopenias and especially lymphopenia, independent of kidney function. This finding has the potential to alter our therapeutic approach to patients with PKD.
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I N T R O D U C T I O N
Hereditary autosomal dominant polycystic kidney disease (PKD) is caused by mutations in genes coding for polycystin-1 and more rarely polycystin-2 and is the most common monogenic disorder, affecting $1 in 500 people. It is the primary cause of end-stage kidney disease (ESKD) in 5-15% of those treated with renal replacement therapy [1, 2] . The disease has a particular phenotype that includes a tendency to develop aneurysms, cardiac valve disorders, abdominal wall hernias and hypertension. Patients with PKD also tend to easily contract ascending urinary tract infections, develop bronchiectasis more readily than chronic kidney disease (CKD) patients without PKD, with an adjusted odds ratio (AOR) of 2.78, and have a higher incidence of pneumonia and nonmelanoma skin cancer, with an AOR of 1.65, than kidney transplant recipients without PKD [2, [3] [4] [5] [6] . This suggests an impaired immune response may be at play.
The proteins polycystin-1 and -2, which form a functional complex, are present in renal tubular epithelial cells. If one of these proteins is dysfunctional, this causes disturbed calcium influx, increased apoptosis and cystogenesis, resulting in the PKD type 1 and 2 phenotypes, respectively [1] . Polycystin-1 and polycystin-2 are not only present in renal tubular cells, but also in cardiomyocytes [7] and endothelial cilia [8] , and their dysfunction could explain the early development of cardiac hypertrophy and endothelial dysfunction in PKD, even with preserved kidney function and at a very young age [9, 10] . It is uncertain whether decreased proliferation of lymphoblastoid cells in PKD in vitro translates into fewer circulating lymphocytes in vivo [11] . We hypothesized that lymphopenia could be more common in PKD, which could explain a higher incidence of infections and skin cancer in this particular population.
In 2002, Banerjee et al. [12] conducted a small unadjusted cross-sectional case-control study and found that among patients treated with haemodialysis, those with PKD (n ¼ 11) had 610/mL (40%) fewer lymphocytes compared with the ageand sex-matched controls without PKD (n ¼ 33).
Aim
We wanted to determine whether lymphocyte counts were lower in patients with PKD than in controls, independent of the effects of kidney function and after adjustment for confounders such as age and inflammation. We also wanted to verify whether differences in lymphocyte counts were confined to specific lymphocyte subpopulations. In secondary analyses, numbers of other leucocyte subtypes and platelets were analysed.
M A T E R I A L S A N D M E T H O D S

Study settings
In the first study, we compared lymphocyte counts of all patients with ESKD with versus without PKD who were admitted to the Ghent University Hospital for kidney transplantation (ESKD cohort). In a second analysis, we gathered data on lymphocyte counts from stable outpatient clinic patients with CKD and PKD from three Belgian hospitals: Ghent University Hospital, AZ Delta Hospital Roeselare and OLV Hospital Aalst (CKD cohort). We compared these participants with age-and sex-matched controls across the same categories of CKD (stage G1-5) but with an alternative renal diagnosis.
The institutional review board and ethics committee of Ghent University Hospital reviewed and approved the research protocol (EC/2015/0655).
Time of assessment
In the people with ESKD and waitlisted for transplantation, we measured the lymphocyte count immediately before transplantation. In the second analysis, we retrieved data from the last measurement at the outpatient clinic from January 1999 to 1 February 2016.
Study population
The study population included: Excluded were patients with acquired cystic disease, renal dysplasia, von Hippel-Lindau disease or autosomal recessive polycystic disease.
Measurements
We selected a priori variables considered for analysis on their theoretical association with lymphocyte count: age, sex, estimated glomerular filtration rate (eGFR) and C-reactive protein (CRP).
We extracted the following baseline clinical characteristics of the ESKD cohort from the transplant database of the Ghent University Hospital, which contains prospectively collected data on baseline characteristics and outcomes of all kidney transplant recipients: continuous variables included age (years) and time on the waiting list (days) and categorical variables included sex (coded as male ¼ 1, female ¼ 0); diabetes at the time of assessment (yes/no), defined according to the American Diabetes Association criteria [13] or as intake of glucose-lowering drugs according to patient records; ethnicity (coded as Caucasian ¼ 0, non-Caucasian ¼ 1); dialysis
; retransplantation (yes/no) and intake of immunosuppressive drugs before transplantation (yes/no).
We extracted from the medical files the following baseline biochemical variables: lymphocytes, haemoglobin, leucocytes, thrombocytes, neutrophils, monocytes, serum albumin, CRP and body mass index (BMI), calculated as weight in kilograms divided by the square of height in metres.
If data on flow cytometric immunophenotyping analysis were available at the time of transplantation, we included counts of CD4 þ T lymphocytes, CD8 þ T lymphocytes, CD19 þ B lymphocytes and natural killer (NK) cells.
Lymphopenia was defined as <1133 lymphocytes/lL of blood according to the laboratory reference values. All participating centres use automated cell counters (Sysmex, Kobe, Japan).
For the CKD cohort, we recorded serum creatinine and calculated eGFR based on the Chronic Kidney Disease Epidemiology Collaboration formula [14] and gathered data on haemoglobin, haematocrit, thrombocytes, leucocytes, monocytes, neutrophils, lymphocytes, erythrocyte sedimentation rate and CRP from the respective databases of each participating centre.
In additional analyses, we examined whether there were differences between leucocyte subpopulations and thrombocyte counts in patients with versus without PKD.
Statistical analysis
We summarized baseline characteristics as means and standard deviations (SDs) or medians with interquartile range (IQR) for continuous and percentages for categorical variables. We analysed differences between groups with independent sample t-tests, Mann-Whitney U-test, analysis of variance, KruskalWallis test and chi-square test depending on the distribution. If appropriate, we used post hoc Scheffé testing to account for multiple comparisons. We used multiple linear regression analysis to study the relation between PKD and lymphocyte concentration as a dependent variable. CRP was natural log transformed (lnCRP) because of its skewed distribution. We constructed models adjusting for a priori specified covariates based on previous literature: age, sex, lnCRP and eGFR (CKD cohort). Additionally, we adjusted for covariates that were statistically significant (P < 0.1) in each separate univariate model. We tested for interactions between PKD and other covariates such as age and eGFR. We calculated the variance inflation factor to evaluate potential multicollinearity.
In the CKD cohort, we matched each case of PKD for age, sex and CKD stage with an individual with an alternative renal diagnosis. We additionally analysed the mean lymphocyte count of the last two consultations as internal validation.
We performed similar analyses to evaluate the association between PKD and leucocyte, monocyte and neutrophil counts, but refrained from multivariable modeling for each haematological covariate considering our main study question and also taking into account the risk of committing type I error due to multiple testing.
A two-sided P-value <0.05 was considered to indicate statistical significance for all analyses. We conducted all statistical analyses using SPSS Statistics (version 22.0; IBM, Armonk, NY, USA).
R E S U L T S ESKD cohort
Between January 2003 and December 2014, 949 patients (mean age of 52 6 12 years, 63% male, 17% diabetes, 95% Caucasian and 12% on immunosuppressive drugs at the time of transplantation) received a kidney transplant at Ghent University Hospital. We excluded 249 patients because the lymphocyte count was unavailable, leaving 700 included in the study. Flow cytometric analysis data were available in 484 participants. The proportion of participants with PKD was similar in the 249 people with missing data (Figure 1 ). There were no missing data on any other covariate. Participants with versus without PKD were 4 years older, were less frequently male and had a comparable CRP concentration. PKD patients had a lower BMI, less frequently had diabetes and only $5% were taking immunosuppressive drugs versus 14% in those without PKD (Table 1) .
Participants with PKD had on average 269 (95% CI 150-388; P < 0.001; 17%) fewer lymphocytes/ll than those without PKD. When defined as <1133 lymphocytes/ll, lymphopenia was $1.6 times as common for those with PKD. Blood concentrations of CD8 þ T lymphocytes and CD19 þ B lymphocytes were 25% and 31% lower, respectively, in people with versus without PKD (both P < 0.001). Patients with PKD also had lower total leucocyte and thrombocyte counts (P < 0.001 for both) (Table 1, Figure 2 , Supplementary Figure S1 ).
Regression model
When adjusted for age, sex and lnCRP, patients with PKD had on average 264 fewer lymphocytes compared with those without PKD [adjusted mean difference À264 cells/mL (95% CI À384 to À144 cells/mL), P < 0.001] ( Table 2 , Model 2). After þ T lymphocytes; CD8, CD8 þ T lymphocytes; B, B lymphocytes; NK, natural killer cells. Differences for haematological tests between people with and without PKD; *P <0.05; ***P < 0.001. The population characteristics of the CKD cohort (n ¼ 408) of age-and sex-matched individuals with CKD across comparable stages are presented in Table 3 . The mean age was 49 6 13 years and 43% were male, 7% had diabetes and the median eGFR was 35 (IQR 4-9) mL/min. There were no differences in CRP concentration and ethnicity. The prevalence of diabetes was $3% in the participants with versus 11% in those without PKD.
The mean lymphocyte count in individuals with PKD was 364/ ml lower than in those without PKD and lymphopenia was about twice as common in participants with PKD. Using the mean lymphocyte count of the last two visits, the difference in lymphocytes between patients with and without PKD remained comparable [360/mL (95% CI 260-460), P < 0.001]. Two measurements of lymphocyte counts were available in 90% of the patients.
Similar to the findings in the ESKD cohort, lymphocyte, monocyte and thrombocyte counts were lower in the people with versus without PKD (P < 0.001 for all), whereas there was no difference in neutrophil count. Although the lymphocyte numbers were lower at more severe stages of CKD for all patients, the difference between lymphocyte counts between the two groups remained significant after stratification for CKD category (Figure 3 , Supplementary Table S1, Figure S2 ), whereas the differences in leucocyte, thrombocyte and monocyte counts were not uniform across the stages of CKD (Supplementary  Table S1 ). Haemoglobin concentrations were significantly lower in patients with more severe stages of kidney disease (P < 0.001), but concentrations were not different between people with and without PKD (Supplementary Table S1 ).
When adjusted for age, sex, lnCRP and eGFR, PKD remained significantly associated with lymphocyte concentration [adjusted mean difference À345/mL (95% CI À445 to À245), P < 0.001] ( Table 2 ). After further adjustment for diabetes, the difference between PKD and non-PKD was À333/mL (95% CI À434 to À233; P < 0.001). We did not observe any clinically meaningful significant interaction between PKD and the other covariates. Also, male sex and lower eGFR were associated with lower lymphocyte counts (Table 4) . Using the mean lymphocyte count of the last two visits, the difference in lymphocytes between patients with and without PKD remained comparable [adjusted mean difference 290/mL (95% CI 185-395); P < 0.001].
Patients with PKD had lower thrombocyte [PKD versus non-PKD À28.10 3 /mL (95% CI À40.10 3 to À16.10
3 ), P < 0.001] and monocyte counts [PKD versus non-PKD À85/mL (95% CI À122 to À47), P < 0.001], while neutrophil counts were not significantly lower (Table 2) .
D I S C U S S I O N
Patients with PKD and ESKD or CKD not on dialysis had lower lymphocyte counts than patients with other aetiologies of kidney failure. The strength of the association was comparable in both study groups and independent of confounders such as age, sex and CRP. In an age-and sex-matched multicentre cohort of patients stratified for CKD category, the association was consistent across all strata, further increasing the external validity of our findings. Since lymphocyte counts and especially of CD4 þ T cells decrease progressively with declining kidney function in line with the previously reported incremental apoptosis with advancing CKD [15] [16] [17] [18] , lymphocyte numbers in patients with and without PKD can only be compared after adjustment for this confounder. The lower number of lymphocytes in patients with PKD is most likely clinically relevant. Lower numbers of lymphocytes in kidney transplant recipients were previously associated with mortality, the development of solid cancer, skin cancer and lymphoma [19] [20] [21] . According to Ducloux et al. [20] , after adjustment for confounders, for each increase in 100/mm 3 of CD4 þ T cells there was a 27% lower risk of developing cancer, with a relative risk (RR) of 0.73 (95% CI 0.62-0.89). The difference in CD4 þ counts at the time of transplantation in our analysis was 77 (95% CI 1-153). For each increase in B cells of 10/mm 3 there was a 13% lower risk of cancer, with a RR of 0.87 (95% CI 0.59-1.02) while the difference in B cells between patients with and without PKD was 50 (95% CI 22-79) in our analysis. PKD increases the risk of squamous cell cutaneous, colon, liver and renal carcinoma in transplant recipients or the general population [2, 6, 22] . Unfortunately, data on lymphocyte counts are lacking in these analyses [2, 6, 22] . Lymphopenia is a wellestablished risk factor for infections in different study populations. Among kidney transplant recipients it is associated with the development of Pneumocystis jiroveci pneumonia (PJP) [23, 24] and in liver transplant recipients, pre-transplant lymphopenia is associated with an increased risk of cytomegalovirus (CMV) and non-CMV invasive infections after transplantation [25] . In another analysis, in liver transplant recipients, pretransplant lymphocytes <1000/mL versus !1000/mL were associated with an increased risk of infections after transplantation in a multivariate model, with an odds ratio of 10.1 (95% CI 1.9-39; P ¼ 0.005) [26] . Prospective analyses should determine whether these baseline differences in lymphocyte counts translate into unfavorable outcomes in PKD patients before or after kidney transplantation.
The differences in cellular differentiation were most pronounced in CD8
þ T lymphocytes and B lymphocytes in the ESKD cohort (Figure 2 ), although we cannot exclude that the relative distribution of differences in lymphocyte counts is coincidental. In particular, the blood concentration of CD4 þ T lymphocytes is expected to decrease with more advanced CKD, while concentrations of CD8 þ T lymphocytes change less [18] . We can speculate on the causal mechanism of our findings. Aberrant expression of polycystin-1 and/or polycystin-2 could lead to decreased proliferation of lymphocytes, as has been shown in a study with Epstein-Barr virus immortalized lymphoblastoid cells [11] . An increased apoptosis rate of lymphoid and myeloid cells remains an interesting alternative hypothesis in line with increased apoptosis of renal tubular epithelial cells in PKD [1, 27] . A targeted deletion of the antiapoptotic B-cell lymphoma 2 (Bcl-2) in mice was both associated with PKD and lymphopenia, especially of CD8 þ lymphocytes, due to an increased rate of apoptosis [28] . Apoptotic pathways, including the intrinsic Bcl-2 pathway, determine the final concentration of circulating lymphocytes [29] and affect the generation and survival of thrombocytes as well [30] . Kidney cells with silenced polycystin-1 expression have increased degradation of Bcl-2, leading to more apoptosis [27] . Disturbed apoptosis could be the common denominator in PKD explaining the renal and haematological phenotype. As such, particularly lymphopenia might reveal itself as a novel biomarker of a more severe phenotype with a faster decline of kidney function. Obviously prospective analyses are needed.
Already in the early stages of kidney failure, lymphopenia might characterize PKD. Of note, lymphopenia in our CKD cohort was more common in males, whose kidney function in PKD was recently shown to decline faster than in females [31] . Since not only lymphocyte but also monocyte and thrombocyte counts were consistently lower in both groups of patients with versus without PKD, we speculate that a distinct genetic defect affects the common progenitor cells, leading to decreased proliferation or increased apoptosis in an early phase of haematopoiesis. In a recent analysis, platelet counts were lower in 290 patients with PKD and ESKD than in age-and sex-matched controls (215 versus 238 Â 10 3 /mL; P < 0.01), whereas the difference was not significant in individuals with CKD and after kidney transplantation [32] . Also, thrombocytopenia in PKD seems to be associated with a more severe renal phenotype with a larger total kidney volume and faster increase of kidney volume and decline of kidney function [33] . Obviously, PKD is characterized by a higher incidence of erythrocytosis [34, 35] , and a lower need for erythropoiesis-stimulating agents [36] . This suggests that other mechanisms (for instance, increased expression of hypoxiainducible factor-1 and/or erythropoietin) might be at play.
Our analysis has some limitations. First, the analysis is crosssectional and as such it is impossible to make causal inferences. Yet, the data from our study align with existing in vitro data on the role of polycystin in lymphocyte proliferation in PKD. Second, data on immunophenotypic analysis in the ESKD cohort were incomplete within the constraints of retrospective data analysis. Also, the lack of a substantial number of lymphocyte subsets precluded imputations. Yet, we believe selection bias is unlikely, as all patients suitable for transplantation were included for analysis. Moreover, the proportion of patients with PKD in the ESKD cohort did not change after excluding patients without available data on lymphocyte counts ( Figure  1 ). Other relevant characteristics did not differ between the groups, suggesting that there was no informed missing data. Third, we cannot exclude that hidden confounders are still present. And while CRP concentrations were not different between groups with and without PKD, we cannot exclude that patients with PKD have some degree of chronic inflammation that was not entirely captured by CRP. By excluding patients with active infection and malignancy, we believe we avoided this confounder to a large extent.
C O N C L U S I O N
PKD is associated with lymphopenia and especially with lower blood concentrations of CD8 þ T and B lymphocytes. This finding could explain the increased risk of pneumonia, urinary tract infections and non-melanoma skin cancer after transplantation in these patients, which might warrant less aggressive immunosuppression in PKD patients after transplantation.
This finding can potentially aid in risk stratification of people with PKD. If mutations in polycystin-1 and/or -2 lead to decreased proliferation of lymphocytes or increased apoptosis of renal tubular epithelial cells and lymphocytes via a common pathway, the degree of lymphopenia might reflect the genotype-phenotype interaction in PKD. As such, lymphopenia could serve as an inexpensive and easily accessible biomarker of a more severe phenotype with a faster decline of kidney function, aneurysm formation or cardiovascular involvement. This hypothesis is amenable to further exploration by prospective observational studies with wide application of disease markers including renal imaging. Also, our study asks for the clarification of a potential role of polycystin in the pathophysiology of haematological disorders and in different health conditions including PKD.
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